Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Stock Competitors & Peer Comparison
See HZNP's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HZNP and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HZNP | $116.30 | +0.00% | 26.6B | 61.86 | $1.88 | N/A |
| LLY | $1,185.71 | -0.52% | 1.1T | 37.64 | $31.49 | +0.55% |
| JNJ | $259.24 | +0.88% | 624.7B | 24.16 | $10.73 | +2.04% |
| ABBV | $246.04 | +0.89% | 434.4B | 24.13 | $10.19 | +2.79% |
| MRK | $128.57 | +0.16% | 317.5B | 40.05 | $3.21 | +2.61% |
| NVS | $156.33 | +1.37% | 297.2B | 17.99 | $8.69 | +3.03% |
| AZN | $161.42 | +0.88% | 250.3B | 17.43 | $9.26 | +1.30% |
| AMGN | $410.95 | +1.51% | 221.8B | 18.37 | $22.37 | +2.39% |
| NVO | $47.26 | +2.81% | 209.8B | 11.75 | $4.02 | +3.82% |
| GILD | $133.21 | +1.80% | 165.4B | -341.56 | -$0.39 | +2.42% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
HZNP vs LLY Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while LLY trades at $1,185.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas LLY's P/E ratio is 37.64. In terms of profitability, HZNP's ROE is +0.11%, compared to LLY's ROE of +0.93%. Regarding short-term risk, HZNP is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
HZNP vs JNJ Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, JNJ has a market cap of 624.7B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while JNJ trades at $259.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas JNJ's P/E ratio is 24.16. In terms of profitability, HZNP's ROE is +0.11%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, HZNP is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
HZNP vs ABBV Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, ABBV has a market cap of 434.4B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while ABBV trades at $246.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas ABBV's P/E ratio is 24.13. In terms of profitability, HZNP's ROE is +0.11%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, HZNP is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
HZNP vs MRK Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MRK has a market cap of 317.5B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while MRK trades at $128.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MRK's P/E ratio is 40.05. In terms of profitability, HZNP's ROE is +0.11%, compared to MRK's ROE of +0.18%. Regarding short-term risk, HZNP is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check MRK's competition here
Novartis AG (NYSE: NVS)
HZNP vs NVS Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVS has a market cap of 297.2B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while NVS trades at $156.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVS's P/E ratio is 17.99. In terms of profitability, HZNP's ROE is +0.11%, compared to NVS's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to NVS. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
HZNP vs AZN Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AZN has a market cap of 250.3B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while AZN trades at $161.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AZN's P/E ratio is 17.43. In terms of profitability, HZNP's ROE is +0.11%, compared to AZN's ROE of +0.22%. Regarding short-term risk, HZNP is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
HZNP vs AMGN Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while AMGN trades at $410.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AMGN's P/E ratio is 18.37. In terms of profitability, HZNP's ROE is +0.11%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, HZNP is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
HZNP vs NVO Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVO has a market cap of 209.8B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while NVO trades at $47.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVO's P/E ratio is 11.75. In terms of profitability, HZNP's ROE is +0.11%, compared to NVO's ROE of +0.59%. Regarding short-term risk, HZNP is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
HZNP vs GILD Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while GILD trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GILD's P/E ratio is -341.56. In terms of profitability, HZNP's ROE is +0.11%, compared to GILD's ROE of -0.16%. Regarding short-term risk, HZNP is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
HZNP vs PFE Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, PFE has a market cap of 152.4B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while PFE trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas PFE's P/E ratio is 8.77. In terms of profitability, HZNP's ROE is +0.11%, compared to PFE's ROE of +0.05%. Regarding short-term risk, HZNP is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
HZNP vs BMY Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BMY has a market cap of 132.2B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while BMY trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BMY's P/E ratio is 10.91. In terms of profitability, HZNP's ROE is +0.11%, compared to BMY's ROE of +0.47%. Regarding short-term risk, HZNP is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check BMY's competition here
GSK plc (NYSE: GSK)
HZNP vs GSK Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GSK has a market cap of 106.1B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while GSK trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GSK's P/E ratio is 11.44. In terms of profitability, HZNP's ROE is +0.11%, compared to GSK's ROE of +0.24%. Regarding short-term risk, HZNP is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check GSK's competition here
Sanofi (NASDAQ: SNY)
HZNP vs SNY Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while SNY trades at $43.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SNY's P/E ratio is 9.47. In terms of profitability, HZNP's ROE is +0.11%, compared to SNY's ROE of +0.06%. Regarding short-term risk, HZNP is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
HZNP vs BIIB Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BIIB has a market cap of 30.7B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while BIIB trades at $207.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BIIB's P/E ratio is 13.13. In terms of profitability, HZNP's ROE is +0.11%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, HZNP is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
HZNP vs ZTS Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, ZTS has a market cap of 30.5B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while ZTS trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas ZTS's P/E ratio is 11.04. In terms of profitability, HZNP's ROE is +0.11%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, HZNP is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check ZTS's competition here
Grifols, S.A. (NASDAQ: GRFS)
HZNP vs GRFS Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GRFS has a market cap of 6.7B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while GRFS trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GRFS's P/E ratio is 9.12. In terms of profitability, HZNP's ROE is +0.11%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, HZNP is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
HZNP vs OGN Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while OGN trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas OGN's P/E ratio is 4.06. In terms of profitability, HZNP's ROE is +0.11%, compared to OGN's ROE of +0.23%. Regarding short-term risk, HZNP is less volatile compared to OGN. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
HZNP vs CELG-RI Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, HZNP is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
HZNP vs CTOR Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CTOR has a market cap of 72.5M. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while CTOR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CTOR's P/E ratio is -1.66. In terms of profitability, HZNP's ROE is +0.11%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, HZNP is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
HZNP vs SCLX Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLX has a market cap of 59M. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while SCLX trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLX's P/E ratio is -0.18. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, HZNP is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
HZNP vs SCLXW Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, HZNP is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
HZNP vs MIRA Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MIRA has a market cap of 31.1M. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while MIRA trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MIRA's P/E ratio is -0.51. In terms of profitability, HZNP's ROE is +0.11%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, HZNP is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
HZNP vs BDSIW Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, HZNP's ROE is +0.11%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, HZNP is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
HZNP vs CRXT Comparison August 2026
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CRXT's P/E ratio is -0.02. In terms of profitability, HZNP's ROE is +0.11%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, HZNP is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for HZNP.Check CRXT's competition here